TABLE 2.
The prevalence of lipodystrophy in different clinical studies
| Study | Number of patients | Type | Definition | Prevalence |
|---|---|---|---|---|
| HOPS (17) | 1057 (85% male) | Cross-sectional | Moderate or severe lipoatrophy and/or lipoaccumulation | Lipodystrophy (total) 49%; lipoatrophy 13.3%; lipoaccumulation 13.2%; mixed syndrome 22.7% |
| HOPS (18) (substudy) | 337 | Longitudinal (to 20 months) | Lipoatrophy | Lipoatrophy 13.1% |
| APS (19) | 1348 (97% male) | Cross-sectional | Lipoatrophy and lipoaccumulation | Lipodystrophy (total) 53%; lipoatrophy 16%; lipoaccumulation 7%; mixed syndrome 29% |
| Salsa (20) | 526 (84% male) | Cross-sectional | Lipoatrophy and lipoaccumulation (questionnaire) | Lipoatrophy – men 67%, women 59%; lipoaccumulation – men 76%, women 93% |
| APROCO (21) | 614 (80% male) | Cross-sectional (12 to 20 months after starting protease inhibitor) | Lipoatrophy and lipoaccumulation | Lipoatrophy 21%; lipoaccumulation 17%; mixed syndrome 24% |
| LIPOCO (22) | 154 (100% male) | Cross-sectional | Lipoatrophy and/or lipoaccumulation | Lipodystrophy (total) 53.2%; lipoatrophy 22.1%; lipoaccumulation 5.9%; mixed syndrome 25.3% |
| MACS (23) | 868 (100% male) | Cross-sectional | Moderate-to-severe lipoatrophy and lipoaccumulation | Mixed syndrome 20% |
APROCO Antiproteases Cohorte; APS Australian Lipodystrophy Prevalence Survey; HOPS HIV Outpatient Study; LIPOCO Lipodystrophie Cohorte; MACS Multicenter AIDS Cohort Study; Salsa Self-Ascertained Lipodystrophy Syndrome Assessment